Evidence map›Paper›PMID 35968737›Full record

ArticleHIV research & clinical practice2022

Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions

Karine Dubé, Harsh Agarwal, William B Carter, Lynda Dee, Jeff Taylor, Christopher Roebuck, Beth Peterson, Hursch Patel, Samuel Ndukwe, Kenneth M Lynn and 13 more

Abstract read
In one paragraph

Article in HIV research & clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Prevention, treatment and cure of HIV infection.Nature reviews. Microbiology · 2023
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Karine DubéUNC Gillings School of Global Public Health, Chapel Hill, NC, USA.ORCID 0000-0003-3458-1539
Harsh AgarwalUNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
William B CarterBEAT-HIV Delaney Collaboratory Community Advisory Board (CAB), Philadelphia, PA, USA.
Lynda DeeAIDS Treatment Activists Coalition (ATAC), Nationwide, Baltimore, MD, USA.
Jeff TaylorAIDS Treatment Activists Coalition (ATAC), Nationwide, Baltimore, MD, USA.
Christopher RoebuckDepartment of Science and Technology Studies, Cornell University, Ithaca, NY, USA.
Beth PetersonWistar Institute and BEAT-HIV Delaney Collaboratory, Philadelphia, PA, USA.
Hursch PatelUNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
Samuel NdukweUNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
Kenneth M LynnHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Linden Lalley-ChareczkoPhiladelphia FIGHT Community Health Centers, Philadelphia, PA, USA.
Emily HiserodtPhiladelphia FIGHT Community Health Centers, Philadelphia, PA, USA.
Sukyung KimHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Daniel RosenbloomMerck & Co, Inc., Kenilworth, NJ, USA.
Brad R EvansMerck & Co, Inc., Kenilworth, NJ, USA.
Melanie AndersonMerck & Co, Inc., Kenilworth, NJ, USA.
Daria J HazudaMerck & Co, Inc., Kenilworth, NJ, USA.
Kevin BatemanMerck & Co, Inc., Kenilworth, NJ, USA.
Bonnie J HowellMerck & Co, Inc., Kenilworth, NJ, USA.
Livio AzzoniWistar Institute and BEAT-HIV Delaney Collaboratory, Philadelphia, PA, USA.
Karam MounzerPhiladelphia FIGHT Community Health Centers, Philadelphia, PA, USA.
Pablo TebasHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Luis J MontanerWistar Institute and BEAT-HIV Delaney Collaboratory, Philadelphia, PA, USA.

Funding

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164570NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HIV InfectionsFemaleHumansLongitudinal StudiesMaleSerologic TestsUnited StatesViral LoadWithholding Treatmentacceptabilityanalytical treatment interruptionsexperimental deviceHIV cure researchHome-based blood collectionparticipant experiencespeople with HIVself-testviral load

Identifiers

PMID35968737
PMCPMC9403870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.